Revolutions Medicines’ daraxonrasib met the principle objectives of its Section 3 take a look at in pancreatic most cancers, posting outcomes that had been each statistically important and clinically significant. The corporate now plans to file for fast regulatory approval below a brand new FDA pilot program.
The submit Revolution Medicines Reviews ‘Unprecedented’ Survival in Pivotal Pancreatic Most cancers Trial appeared first on MedCity Information.
